Skip to main content
Smart Investors Daily
TP

NASDAQ · TPST

Tempest Therapeutics, Inc.

Healthcare · Biotechnology

$0.38

Down-$0.04 (-10.50%)

Updated Nov 17, 2026, 1:19 AM

SID Score

2.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
14.1M
P/E ratio
-0.28
Dividend yield
0.00%
52-week range
$0.34 – $4.88
Volume
153.52K
Avg. volume
107.23K

Price performance · TPST

TPST price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 13, 2026

TPST closed at $0.38 after 20 trading sessions, down 36.36% for the selected period.

Last close
$0.38
Period change
-36.36%
Period low
$0.36
Period high
$0.60
Daily close
View OHLC price history
TPST OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 13, 2026$0.383$0.3898$0.3641$0.3819153.52K
Nov 12, 2026$0.379$0.3997$0.3701$0.383131.77K
Nov 11, 2026$0.4206$0.4766$0.379$0.3971.48M
Nov 10, 2026$0.3971$0.3997$0.3367$0.3742295.32K
Nov 9, 2026$0.3902$0.4083$0.36$0.3614238.45K
Nov 6, 2026$0.41$0.41$0.38$0.380686.1K
Nov 5, 2026$0.4785$0.4799$0.3706$0.3752316.69K
Nov 4, 2026$0.462$0.4997$0.4552$0.4633108.52K
Nov 3, 2026$0.4965$0.4999$0.4638$0.4686140.98K
Nov 2, 2026$0.50$0.507$0.4701$0.472160.45K
Oct 30, 2026$0.5333$0.5466$0.4902$0.4955163.47K
Oct 29, 2026$0.549$0.5597$0.53$0.533257.16K
Oct 28, 2026$0.515$0.5399$0.5102$0.5399103.81K
Oct 27, 2026$0.5174$0.5305$0.5105$0.510779.24K
Oct 26, 2026$0.5076$0.5212$0.5005$0.510266.15K
Oct 23, 2026$0.5342$0.542$0.5039$0.51152.25K
Oct 22, 2026$0.5162$0.55$0.5162$0.5223195.96K
Oct 21, 2026$0.57$0.623$0.5202$0.5282372.89K
Oct 20, 2026$0.6004$0.6281$0.573$0.5762144.97K
Oct 19, 2026$0.64$0.64$0.60$0.6001128.47K

Latest TPST news

The latest Smart Investors Daily articles mentioning TPST.

TPST research

Overview

Company profile and research snapshot.

Company profile

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
TPST recent ratings
DateFirmRatingTarget
Sep 24, 2026HC Wainwright & Co.Buy—
Jan 22, 2026HC Wainwright & Co.Buy—
Apr 10, 2025ScotiabankSector Perform—
Apr 10, 2025HC Wainwright & Co.Neutral—
Mar 28, 2025ScotiabankSector Outperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 11, 2026

Tempest Therapeutics Exercises Option to License Senlang’s CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D Candidate

-Tempest secures exclusive global rights outside China to a targeted lentiviral platform and portfolio of in vivo CAR-T candidates -Lead BCMA/GPRC5D dual-targeting in vivo CAR-T candidate evaluated in 13 patients with relapsed or refractory multiple myeloma, including patients with extramedullary disease and prior CAR-T exposure -Encouraging preliminary clinical responses support option exercise, results planned for presentation at a major scientific conference BRISBANE, Calif., Nov. 11, 2026 (G

Yahoo · Oct 14, 2026

Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise

BRISBANE, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing in vivo CAR-T therapies designed to reset dysfunctional immunity in cancer and autoimmune disease, today announced that John W. Frederick has been appointed to its board of directors. Mr. Frederick brings extensive executive leadership experience spanning financial strategy, capital markets, corporate governance and operational transformatio

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.